Monitor for subsequent data readouts and PMA submission progress; approval would open a significant market opportunity, but regulatory and funding risks remain high. Historical stock reaction to clinical milestones on this ticker has been muted or negative, suggesting tempered expectations.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $1.02entry
- T+1 · 6mo ago 0.00%α −0.23% · $1.02
- T+5 · 6mo ago 0.00%α −1.46% · $1.02
- T+20 · 5mo ago 0.00%α −0.02% · $1.02
- T+60 · 3mo ago +223.53%α +218.69% · $3.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau completed enrollment of 88 patients in its U.S. pivotal ReSTART trial for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key milestone toward potential FDA PMA approval. The company has Breakthrough Device Designation and initiated the modular PMA process in January 2026. No financial data was provided; the event is a clinical milestone with no revenue impact yet.
Key Facts
- Enrolled all 88 patients in the ReSTART pivotal trial for recurrent cSCC
- First U.S. pivotal study to complete enrollment for Alpha Tau
- Alpha DaRT received Breakthrough Device Designation from FDA
- First module of modular PMA application submitted in January 2026
- Study co-primary endpoints: objective response rate and duration of response at 6 months
Financial Impact
No financial figures reported; potential future revenue contingent on FDA approval, currently pre-revenue
Risk Factors
- FDA approval not guaranteed; pivotal trial results may not meet endpoints
- Company has significant losses and may need additional capital to fund operations and commercialization
- Competition from other skin cancer treatments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053589 |
| Document: ea028978301-6k_alphatau.htm | 0001213900-26-053589 |
| Document: 0001213900-26-053589-index-headers.html | 0001213900-26-053589 |
| Document: 0001213900-26-053589-index.html | 0001213900-26-053589 |
| Document: 0001213900-26-053589.txt | 0001213900-26-053589 |
Track record
14 reports on DRTSW
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Viewing Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers